National Institute on Drug Abuse; Notice of Closed Meeting, 42825 [2017-19233]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 175 / Tuesday, September 12, 2017 / Notices
Name of Committee: National Institute on
Aging Special Emphasis Panel; Resource
Centers for Minority Aging Research
(RCMAR) ZAG1 ZIJ–9 J2.
Date: October 31–November 1, 2017.
Time: 5:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, MD 20814.
Contact Person: Carmen Moten, Ph.D.,
MPH, Scientific Review Officer, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7703, cmoten@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: September 6, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–19231 Filed 9–11–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
pmangrum on DSK3GDR082PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Products to Prevent (Lethal) Drug-induced
Respiratory Depression (8942).
Date: September 26, 2017.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Lyle Furr, Scientific
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4227, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
9550, (301) 827–5702, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No.: 93.279, Drug Abuse and
VerDate Sep<11>2014
15:19 Sep 11, 2017
Jkt 241001
Addiction Research Programs, National
Institutes of Health, HHS).
Dated: September 6, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–19233 Filed 9–11–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Biannual Infrastructure
Development Measures for State
Adolescent and Transitional Aged
Youth Treatment Enhancement and
Dissemination Implementation (SYT–I)
and Adolescent and Transitional Aged
Youth Treatment Implementation (YT–
I) Programs—(OMB No. 0930–0344)—
Revision
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Substance Abuse
Treatment has developed a set of
infrastructure development measures in
which recipients of cooperative
agreements will report on various
benchmarks on a semi-annual basis. The
infrastructure development measures
are designed to collect information at
the state-level and site-level.
The projects were previously named
State Adolescent Treatment
Enhancement and Dissemination (SAT–
ED) and State Youth Treatment
Enhancement and Dissemination (SYT–
ED) Programs and are now called State
Adolescent And Transitional Aged
Youth Treatment Enhancement and
Dissemination Implementation (SYT–I)
and Adolescent and Transitional Aged
Youth Treatment Implementation (YT–I)
Programs.
No changes have been made to the
Biannual Infrastructure Development
Measures Report. The only revision to
the biannual progress report is due to
the decrease in the number of
respondents. The infrastructure
development measures are based on the
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
42825
programmatic requirements conveyed in
TI–15–004, Cooperative Agreements for
SYT–I and TI–17–002, Cooperative
Agreements for YT–I.
The purpose of this program is to
provide funding to States/Territories/
Tribes to improve treatment for
adolescents and transitional age youth
through the development of a learning
laboratory with collaborating local
community-based treatment provider
sites. Through the shared experience
between the State/Territory/Tribe and
the local community-based treatment
provider sites, an evidence-based
practice (EBP) will be implemented,
youth and families will be provided
services, and a feedback loop will be
developed to enable the State/Territory/
Tribe and the sites to identify barriers
and test solutions through a services
component operating in real time. The
expected outcomes of these cooperative
agreements will include needed changes
to State/Territorial/Tribal policies and
procedures; development of financing
structures that work in the current
environment; and a blueprint for States/
Territories/Tribes and providers that
can be used throughout the State/
Territory/Tribe to widen the use of
effective substance use treatment EBPs.
Additionally, adolescents (ages 12 to
18), transitional age youth (ages 18 to
24), and their families/primary
caregivers who are provided services
through grant funds will inform the
process to improve systems issues.
Estimates for response burden were
calculated based on the methodology
(survey data collection) being used and
are based on previous experience
collecting similar data and results of the
pilot study. For emailed biannual
surveys, burden estimates of 12.0 hours
were used for Project Directors and/or
Program Managers and burden estimates
of 7.2 hours were used for other project
staff members. It is estimated that 11
Project Directors and/or Program
Managers and 22 other staff members
from Cohort 1 will respond to the
emailed survey biannually (i.e., twice
each year) for 3 years at an estimated
total burden of 1,742.4 hours for Cohort
1. It is estimated that 2 Project Directors
and/or Program Managers and 4 other
staff members from Cohort 2 will
respond to the emailed survey
biannually (i.e., twice each year) for 3
years at an estimated total burden of
316.8 hours for Cohort 2. It is estimated
that 11 Project Directors and/or Program
Managers and 22 other staff members
from Cohort 3 will respond to the
emailed survey biannually (i.e., twice
each year) for 3 years at an estimated
total burden of 1,742.4 hours for Cohort
3. The burden hours of Cohort 1 (1,742.4
E:\FR\FM\12SEN1.SGM
12SEN1
]]>Agencies
[Federal Register Volume 82, Number 175 (Tuesday, September 12, 2017)]
[Notices]
[Page 42825]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19233]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Products to Prevent (Lethal) Drug-induced
Respiratory Depression (8942).
Date: September 26, 2017.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Lyle Furr, Scientific Review Officer, Office of
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,
Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
9550, (301) 827-5702, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance Program No.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS).
Dated: September 6, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-19233 Filed 9-11-17; 8:45 am]
BILLING CODE 4140-01-P
